Literature DB >> 8078064

Botulinum toxin: dangerous terminology errors.

M F Brin, A Blitzer.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8078064      PMCID： PMC1294075     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  5 in total

Review 1.  Interventional neurology: treatment of neurological conditions with local injection of botulinum toxin.

Authors:  M F Brin
Journal:  Arch Neurobiol (Madr)       Date:  1991

2.  Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis.

Authors:  P Greene; U Kang; S Fahn; M Brin; C Moskowitz; E Flaster
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

3.  Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients.

Authors:  I T Lorentz; S S Subramaniam; C Yiannikas
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

4.  Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias.

Authors:  A Blitzer; M F Brin; S Fahn; D Lange; R E Lovelace
Journal:  Laryngoscope       Date:  1986-11       Impact factor: 3.325

Review 5.  The action of batulinum toxin at the neuromuscular junction.

Authors:  L C Sellin
Journal:  Med Biol       Date:  1981-02
  5 in total
  19 in total

1.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Authors:  D Ranoux; C Gury; J Fondarai; J L Mas; M Zuber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Cervical Dystonia (Torticollis).

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

3.  Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.

Authors:  Dirk Dressler; Gerd Mander; Klaus Fink
Journal:  J Neural Transm (Vienna)       Date:  2011-10-05       Impact factor: 3.575

4.  Acute and long-term effects of botulinum neurotoxin on the function and structure of developing extraocular muscles.

Authors:  Scott A Croes; Larisa M Baryshnikova; Soniya S Kaluskar; Christopher S von Bartheld
Journal:  Neurobiol Dis       Date:  2007-01-10       Impact factor: 5.996

5.  Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.

Authors:  K Wohlfarth; I Schwandt; F Wegner; T Jürgens; G Gelbrich; A Wagner; U Bogdahn; W Schulte-Mattler
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

Review 6.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

7.  Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.

Authors:  Dirk Dressler; Lizhen Pan; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2018-06-26       Impact factor: 3.575

8.  Detection of botulinum neurotoxin serotype A, B, and F proteolytic activity in complex matrices with picomolar to femtomolar sensitivity.

Authors:  F Mark Dunning; Daniel R Ruge; Timothy M Piazza; Larry H Stanker; Füsûn N Zeytin; Ward C Tucker
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

9.  Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.

Authors:  Katja Kollewe; Bahram Mohammadi; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-05-01       Impact factor: 3.575

10.  Clinical Pharmacology of Botulinum Toxin Drugs.

Authors:  Dirk Dressler
Journal:  Handb Exp Pharmacol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.